MedTrace Logo

CAR-T Cells in Treating Patients With Relapsed or Refractory NHL

NCT04626739 · Status: UNKNOWN · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2020-11-13

No results posted yet for this study

Summary

This is an open, single-arm, phase I clinical study to evaluate efficacy and safety of chimeric antigen receptor T cell immunotherapy (CAR-T) in the treatment of Non-hodgkin's lymphoma. A total of 100 patients are planned to be enrolled over a period of 3 years.

Conditions

  • Refractory Indolent Adult Non-Hodgkin Lymphoma

Interventions

DRUG

CD19 CAR-T

CD19 CAR-T for CD19 positive R/R non-Hodgkin lymphoma

DRUG

CD22 CAR-T

CD22 CAR-T for CD22 positive R/R non-Hodgkin lymphoma

DRUG

CD19+CD22 CAR-T

CD19+CD22 CAR-T for CD19 positive and CD22 positive R/R non-Hodgkin lymphoma

DRUG

Fludarabine

25mg/㎡ for D-4、D-3 and D-2

DRUG

Cyclophosphamide

500mg/㎡ for D-3 and D-2

Sponsors & Collaborators

  • Hebei Senlang Biotechnology Inc., Ltd.

    lead INDUSTRY

Principal Investigators

  • Jianmin luo, PhD&MD · The Second Hospital of Hebei Medical University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-04-01
Primary Completion
2023-03-30
Completion
2023-03-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04626739 on ClinicalTrials.gov